trending Market Intelligence /marketintelligence/en/news-insights/trending/A1Y2X-xztnF2wA4WPuJzQg2 content esgSubNav
In This List

Cooper Cos. posts 16% YOY rise in fiscal Q4'17

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Video

S&P Capital IQ Pro | Powering Your Edge

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Cooper Cos. posts 16% YOY rise in fiscal Q4'17

The Cooper Cos. Inc. reported a 16% year-over-year rise in fiscal fourth-quarter 2017 earnings and disclosed its guidance for fiscal year 2018.

The medical device company's non-GAAP EPS for the three-month period ended Oct. 31 amounted to $2.65, up from $2.28 in the year-ago period.

The S&P Capital IQ consensus normalized EPS estimate for the quarter was $2.65.

The company's GAAP net income attributable to Cooper stockholders totaled $88.6 million, or $1.78 per share, up from $60.5 million, or $1.23 per share, during the August-October 2016 period.

Net sales over the three-month period rose 8% year over year to $561.5 million from $518.7 million.

The company recorded research and development expense of $18.5 million during the quarter, an increase from $18 million a year ago.

For the full year ended Oct. 31, 2017, Cooper reported non-GAAP EPS of $9.70, up 15% from $8.44 in fiscal year 2016.

The S&P Capital IQ consensus normalized EPS estimate for fiscal 2017 was $9.71.

For fiscal year 2017, GAAP net attributable income rose year over year to $372.9 million, or $7.52 per share, from $273.9 million, or $5.59 per share.

Cooper forecasts non-GAAP EPS to range between $11.35 and $11.65 for the year ending Oct. 31, 2018. The company anticipates total revenue of between $2.48 billion and $2.53 billion for fiscal year 2018.